{"id":43386,"date":"2025-10-15T12:34:51","date_gmt":"2025-10-15T04:34:51","guid":{"rendered":"https:\/\/flcube.com\/?p=43386"},"modified":"2025-10-15T12:34:51","modified_gmt":"2025-10-15T04:34:51","slug":"shandong-buchang-names-goodfellow-as-exclusive-philippine-distributor-for-efparepoetin-alfa-to-treat-ckd-anemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43386","title":{"rendered":"Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin\u202fAlfa to Treat CKD Anemia"},"content":{"rendered":"\n

Shandong Shandong\u202fBuchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin\u202fAlfa to Treat CKD Anemia Co.,\u202fLtd.<\/strong> (SHA: 603858<\/a>) announced today that its subsidiary, Luzhou Buchang<\/strong>, will sign an exclusive supply agreement with GOODFELLOW<\/strong>, a leading Philippine pharmaceutical company. Under the deal, Goodfellow will become the sole distributor for Efparepoetin\u202fAlfa Injection<\/strong> in the Philippines, handling registration, clinical trials, promotion, distribution and sales of the product in the target region.<\/p>\n\n\n\n

Deal Highlights<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Luzhou\u202fBuchang (China) & GOODFELLOW (Philippines)<\/td><\/tr>
Product<\/strong><\/td>Efparepoetin\u202fAlfa Injection \u2013 recombinant EPO\u2011IgG2 fusion protein<\/td><\/tr>
Scope<\/strong><\/td>Exclusive registration, clinical development, marketing and sales in the Philippines<\/td><\/tr>
Target Indication<\/strong><\/td>Anemia caused by chronic kidney disease (CKD) in adult dialysis patients on EPO therapy<\/td><\/tr>
Regulatory Status<\/strong><\/td>Class\u202f1 new biological product; marketing\u2011authorization application already submitted in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

About Efparepoetin\u202fAlfa<\/h2>\n\n\n\n